Log In Get Started
Press Releases May 28, 2026 04:05 PM

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

Equillium to present at 2026 Jefferies Global Healthcare Conference

By Derek Hwang EQ

Equillium, Inc., a biotech company focused on therapies for autoimmune and inflammatory disorders, announced its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference, providing an opportunity to engage with investors.

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
EQ

Key Points

  • Equillium management to participate in a fireside chat at a major healthcare conference.
  • Opportunity to meet and engage with investors attending the conference.
  • Company focuses on developing novel therapies for severe autoimmune and inflammatory diseases.

LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT.

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

For more information, visit www.equilliumbio.com.

Investor Contact 
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
[email protected]


Risks

  • No specific new product or clinical data announced, reliance on future developments for growth.
  • Market and investor reception depends on progress in clinical trials and regulatory approvals.
  • Biotechnology sector risks including clinical trial failures, regulatory hurdles, and competitive landscape.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Telesat announces results of 2026 Annual General Meeting of shareholders Jun 4, 2026 TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology Jun 4, 2026 Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026